China’s innovative drug out-licensing deals have reached a record high of about $110 billion between January and June, according to state broadcaster CCTV, citing data from the National Medical Products Administration.
The deals covered therapeutic areas including oncology, metabolism, immunology, and neurology, with main licensee companies coming from countries such as the U.S., Britain, France, and Italy.
Global drugmakers are stepping up their search for China-developed experimental medicines ahead of patent expirations, driving the growth in deal value.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
